William Oh

Biography
William K. Oh, M.D., is currently the Director of Precision Medicine at Yale Cancer Center and a Professor of Medicine (Medical Oncology) at Yale School of Medicine, roles he assumed in October 2024. As part of a newer initiative at Yale, he is focused on building a cohesive program in precision cancer medicine that integrates basic and translational science, clinical trials, and Smilow Cancer Hospitals Precision Medicine Tumor Board. A central goal of his work is to increase the routine use of molecular and genetic testing for all cancer patients to improve outcomes. Dr. Oh is also dedicated to delivering multidisciplinary care for prostate cancer patients, a priority he has maintained for over 25 years. He has been recognized as a Top Doctor by Castle Connolly, New York Magazine, and Super Doctors. Additionally, he continues his commitment to teaching and advancing research in the field.Previously, Dr. Oh was a Clinical Professor of Medicine at Icahn School of Medicine. He is an internationally recognized medical oncologist with extensive experience in clinical and translational research, holding leadership roles in both academia and industry. He has authored more than 350 articles, reviews, books, and book chapters related to genitourinary cancers. Dr. Oh has conducted numerous clinical cancer trials and served in key invited roles for ASCO, ACS, and AUA. He has also held the position of Chief Medical Officer for Sema4, a genomics and health intelligence company, as well as the Prostate Cancer Foundation.

Nigam Shah

Biography
Dr. Nigam Shah's research is focused on bringing AI into clinical use, safely, ethically and cost-effectively. He holds an MBBS from Baroda Medical College, India, a PhD from Penn State University and completed postdoctoral training at Stanford University. Dr. Shah is an inventor on eight patents, has authored over 300 scientific publications, and has co-founded three companies. Dr. Shah was inducted into the American College of Medical Informatics (ACMI) in 2015 and the American Society for Clinical Investigation (ASCI) in 2016.

David Entwistle

Biography
David Entwistle is the president and CEO of Stanford Health Care. He joined Stanford Health Care in July 2016 with extensive executive experience at leading academic medical centers. Entwistle is a passionate advocate of precision health tailoring a treatment to a patients specific disease or condition as well as prevention to empower patients to take charge of their health before they become ill. Among the factors that attracted him to Stanford Health Care are the unparalleled technologies available in Silicon Valley that help advance health care through the better application of technology for individuals. According to Entwistle, Stanford Health Care is extremely well situated to be able to apply innovative technology, such as wearable devices that track activity or monitor blood glucose levels, to improve health. Entwistle is an avid cyclist who enjoys both road and mountain biking, often accompanied by his teenage son. He also competes in IRONMAN Triathlons.

Brigham Hyde

Biography
Dr. Brigham Hyde is CEO and co-founder of Atropos Health since August 2022. He provided funding and support for Atropos Healths official launch in late 2020. Hyde has a significant track record of building businesses in the health tech and real-world data (RWD) space and previously served as President of Data Analytics at Eversana. Prior to that role, Hyde served as a healthcare partner at the AI venture fund Symphony AI, where he led the investment in, co-founded, and operated Concert AI, an oncology RWD company valued at $1.9B. Hyde held previous roles as Chief Data Officer at Decision Resources Group, which was acquired by Clarivate for $900M in 2020. He has also served on the Global Data Science Advisory Board for Janssen, as a research faculty at MIT Media Lab, and served as adjunct faculty at Tufts Medical School.

Matthew Solomon

Biography
Dr. Matthew Solomon joined Sutter Health as its inaugural chief scientific officer in January 2025. In this role, he is advancing research, medical education, and scientific initiatives to elevate clinical excellence across the system.An internationally recognized cardiologist and scientist, Dr. Solomon has more than 12 years of leadership experience developing data-driven programs that strengthen research, guide clinical operations, and enhance patient care. His work includes leveraging AI and machine learning for diagnostic decision-making and predictive modeling to support proactive population health. He most recently served as a physician-scientist at Kaiser Permanente, where he helped shape data-informed clinical strategies.At Sutter, he collaborates with leaders in digital health, innovation, and clinical service lines, while continuing his practice at California Pacific Medical Center. He is also building a system-wide program for patients with aortic disease, an area in which he is internationally known.

Karan Singhal

Biography
Karan Singhal is a leading researcher in artificial intelligence, specializing in the intersection of AI and healthcare. He currently heads the Health AI team at OpenAI, where he focuses on developing large language models (LLMs) that aim to make medical expertise universally accessible and ensure safety in high-stakes health applications.Before joining OpenAI, Singhal was instrumental in the development of Med-PaLM and Med-PaLM 2 at Google, AI models designed for medical question answering. These models were integrated into Google Cloud and received recognition in prominent publications such as Nature, Scientific American, The Economist, and the BBC.

Emily Alsentzer

Biography
Dr. Emily Alsentzer develops machine learning and natural language processing methods to support clinical decision-making and expand access to high-quality healthcare. Her research focuses on building clinically deployable models that are generalizable, robust, and integrated with medical expertise to ensure safe and responsible use in healthcare workflows. Previously, she was a postdoctoral fellow at Brigham and Womens Hospital, where she helped implement ML models across the Mass General Brigham health system. She received her PhD in the HarvardMIT Health Sciences and Technology program and BS and MS degrees from Stanford. Professor Alsentzers work bridges computer science and clinical communities, with publications in venues such as NeurIPS, NAACL, NEJM AI, Lancet Digital Health, Nature Communications, NPJ Digital Medicine, CHIL, ML4H, PSB, JAMIA, and Communications Medicine. She has also served as General Chair for ML4H and CHIL and as a founding organizer for SAIL and CHIL.

Sina Bari

Biography
Plastic and Reconstructive Surgeon Sina Bari, MD, is a leading medical and information technology innovator. His knowledge and expertise are well-respected across the industry as a considered voice in the development of Medical Artificial Intelligence. In January 2022, Dr. Bari joined iMerit Technology to help the worlds leading medtech companies train safe, high-quality AI systems. At iMerit, Dr. Bari has created and led the healthcare division from ideation to the leading company in the space. Medical AI is a dynamic field where large-scale datasets harness human intelligence to train computer neural networks. Dr. Baris work has significantly improved patient access and care in radiology, endoscopy, robotic surgery, drug development, and drug safety.

Kate Estep

Biography
Kate leads the Product teams responsible for evolving our Point of Care and Evidence Solutions product suites in partnership with customers across oncology providers and life sciences, respectively. Since joining Flatiron in 2018, she has launched new products, evolved mature products, and managed teams of various sizes across the organization.Prior to joining Flatiron, Kate worked for Deloitte's Consulting where she led digital transformations in support of life sciences, public health agencies, and transportation industries.Kate received a bachelor's degree in biomedical engineering from the University of Virginia.

Phil Johnson

Biography
Phil Johnson is a recognized leader in advancing healthcare innovation through real-world data and digital health solutions. At Evidation, he leverages a community of over 5 million individuals and innovative direct-to-patient, longitudinal data capture capabilities to advance patient-centric health research and accelerate drug development.With deep expertise in technology and real-world data, Phil has a proven track record of improving research and patient outcomes. His previous work includes building Real-World Data initiatives and promoting Clinical Diversity at Tempus AI, as well as launching a healthcare and life sciences division at Amazon Web Services, where he forged strategic partnerships with leading U.S. healthcare organizations.

Okan Ekinci

Biography
Okan Ekinci, MD, MBA, is the Head of Digital Technology and Chief Medical Information Officer at Roche Information Solutions. He joined Roche in 2018 and served as Chief Medical Officer and Senior Vice President of Marketing Innovation for the digital health business. Before that, Okan held various positions at Siemens Healthineers, including Chief Medical Officer and Head of Healthcare Consulting. Drawing on extensive experience across imaging, diagnostics, and pharma, he has advised healthcare institutions and governments on strategies for digital transformation, personalized healthcare, and artificial intelligence. Okan is a cardiologist by training and an adjunct professor of medicine at the University College Dublin.

Erwin Estigarribia

Biography
Erwin Estigarribia is the Chief Executive Officer of Headlamp Health, leading the companys mission to deliver the right medication to the right patient at the right time. With over 25 years of international experience in life sciences, Erwin has founded and scaled ventures at the intersection of data, biotechnology, and clinical care. At Headlamp, he is driving the creation of the first agentic AI platform for neuroscience, integrating multimodal patient data to advance precision in diagnosis, treatment, and research. By replacing trial-and-error psychiatry with data-driven precision medicine, Headlamp is transforming mental healthcare and redefining how psychiatric conditions are understood and treated worldwide.

---

Talk
Agentic Intelligence for Precision Neurocience
Agentic Intelligence for Precision Neurosciences integrates multimodal biological, clinical, and behavioral data through adaptive, process-engineered frameworks. These systems learn from biology and workflow feedback, reducing years of frustration for clinicians and patients while derisking clinical trials. The result: biology-informed, actionable intelligence that accelerates discovery and precision care.

Zachary Ziegler

Biography
Zachary Ziegler is the cofounder and CTO of OpenEvidence, the leading AI-powered medical information platform. Designed from the ground up for medical professionals, OpenEvidence organizes the worlds medical knowledge to make it more useful, open, accessible, and understandable. Launched out of the Mayo Clinic Platform Accelerate, OpenEvidence has become a critical tool in physicians tool boxes, used by over a quarter of US physicians in over 10,000 care centers across the United States. Before founding OpenEvidence, Ziegler was a PhD student at Harvard University, where he worked with Professor Sasha Rush and was awarded the National Science Foundation Graduate Research Fellowship. He completed his undergraduate studies at Cornell University, where he received the Barry Goldwater Scholarship.

Michael Pfeffer

Biography
Michael A. Pfeffer, MD, FACP serves as Chief Information and Digital Officer and Associate Dean for Stanford Health Care and Stanford University School of Medicine. Michael oversees Technology and Digital Solutions (TDS), responsible for providing world class technology solutions to Stanford Health Care and School of Medicine, enabling new opportunities for groundbreaking research, teaching, and compassionate care across two hospitals and over 150 clinics. TDS supports Stanford Medicines mission to improve human health through discovery and care and strategic priorities to be value focused, digitally driven, and uniquely Stanford.Michael is a Clinical Professor in the Department of Medicine and Division of Hospital Medicine with a joint appointment in the center for Biomedical Research (BMIR) in Stanford University School of Medicine.

Hal Paz

Biography
Dr. Paz has served as an executive and board member across providers, payers, and med-tech. He was EVPCMO of CVS HealthAetna; ChancellorCEO of Ohio State Wexner Medical Center; and CEO of Penn State Health and Stony Brook Univ Medicine. He sits on the boards of Envision Healthcare and ResearchAmerica and previously served on Select Medical, USPI, Vyteris, and seven health-system boards. He advises Curai Health and previously advised Johnson Johnson and USPI. He has served on committees of the National Academy of Medicine and the National Academies. A former medical school dean and investigator in sepsis, ARDS, and medical devices, he has authored over 100 publications. Dr. Paz earned his BA and MD at the University of Rochester and an MS in life science engineering at Tufts, trained at Northwestern, and completed fellowships at Johns Hopkins in pulmonary and critical care and in environmental health sciences.

Rich Gliklich

Biography
Dr. Rich Gliklich is the founder of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles and then as an XIR with General Catalyst Partners where OM1 was started.Dr. Gliklich is well known in the areas of outcomes, registries and AI. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. . Dr. Gliklich holds more than 10 patents in clinical AI and outcomes.Dr. Gliklich is a graduate of Yale University and Harvard Medical School and is a surgeon and professor, part time, at Harvard Medical School.

---

Talk
Predict What's Next: An AI Transforming Healthcare
Trained on billions of patient-years of RWD, PhenOM is a foundation model that powers digital phenotyping and predicts medical events and outcomes. It accelerates patient finding for undiagnosed conditions, predicts risks of costly events and disease progression, and estimates treatment effects for individuals and populations. Learn how this AI is used across healthcare stakeholders.

Vincent Liu

Biography
Vincent Liu, MD, MS, is a senior research scientist at the Kaiser Permanente Northern California Division of Research, and Chief Data Officer for The Permanente Medical Group. He also directs the Systems Research Initiative, a multidisciplinary team at the Division of Research supported by The Permanente Medical Group (TPMG). His work focuses on the intersection of sepsis, acute severe illness, informatics, and health care delivery with a goal of building towards a learning hospital system. He is a widely recognized expert in applied informatics.Dr. Liu is board certified in Internal Medicine, Pulmonary Disease, Critical Care Medicine, and Clinical Informatics. He practices pulmonary and critical care medicine with TPMG.Dr. Liu is the Regional Director of Hospital Advanced Analytics in Kaiser Permanente Northern California. He has led and served on committees for the American Thoracic Society, the Society of Critical Care Medicine, the National Quality Forum, and the National Institute for General Medical Services. He has served on multiple NIH grant review committees and the National Commission on Quality Assurances Utilization Measure Advisory Panel. He is an editorial board member for Critical Care Medicine.He is also an active mentor and leads the TPMG Informatics Fellowship Program.Dr. Liu received his undergraduate degree from the University of Pennsylvania and his medical degree from New York University. He completed his residency training at New York University Hospitals (Bellevue) and a chief residency at Memorial Sloan-Kettering Cancer Center. He also completed a pulmonary and critical care medicine fellowship and has masters degrees in Health Services Research and Biomedical Informatics, both from Stanford University.

Jorge Durand

Biography
As a medical strategy lead at Klick, Jorge oversees and ensures clinical and scientific relevance across communications and tactics that strategically influence shifts in beliefs and behavior, and move the market landscape. For over 17 years, Jorge has worked in healthcare brands in the US and global markets, across a wide range of therapeutic areas, including rare disease and oncology. Jorge has also led a diverse array of initiatives engaging with thought leaders, patients and caregivers, and patient advocate organizations. Since joining Klick in 2017, Jorge has helped expand their portfolio, as well as our medical strategy team from 3 strategists to currently over 30.Jorge is particularly passionate about bringing forward novel perspectives on the science of a molecule, current clinical practice and market dynamics, especially in brands that have a significant impact on patients lives.

---

Talk
AI-augmented everyday clinical practice -how close are we?
AI is transforming diagnostics, clinical operations, and decision support by improving accuracy, speed, and consistency. Yet clinical context keeps evolvingshaping how we map biology, reveal disease mechanisms, and accelerate target and biomarker discovery. Ultimately, AIML will fulfill their promise only with rigorous validation, strong governance, and active bias mitigation to ensure safe, equitable, responsible care.

Thomas Fuchs

Biography
Dr.sc. is a pioneer in AI for human health and coined the term Computational Pathology. His deep-learning systems for whole-slide images helped establish clinical-grade AI in oncology and built petabyte-scale AI infrastructure, enabling faster, more accurate diagnosis and accelerating precision treatment decisions across the globe. His research has advanced the field by linking tissue morphology to molecular drivers and outcomes across massive datasets. Dr. Fuchs founded Paige AI, a leader in AI-based digital pathology, who received the first breakthrough designation for any AI in oncology and the first FDA approval for an AI in pathology. He previously held influential academic roles, including Dean and endowed Barbara T. Murphy professor for AI & Human Health and Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. As inaugural chair, he founded the first department for AI at a medical school in the US and previously was Director of Computational Pathology at Memorial Sloan Kettering Cancer Center. Trained in machine learning at ETH Zurich, with earlier research at the California Institute of Technology and NASA’s Jet Propulsion Laboratory, he now serves as Eli Lilly’s first Chief Artificial Intelligence Officer, guiding AI across drug discovery, clinical development, manufacturing, finance and commercialization

Thomas Fuchs

Biography
Dr.sc. is a pioneer in AI for human health and coined the term Computational Pathology. His deep-learning systems for whole-slide images helped establish clinical-grade AI in oncology and built petabyte-scale AI infrastructure, enabling faster, more accurate diagnosis and accelerating precision treatment decisions across the globe. His research has advanced the field by linking tissue morphology to molecular drivers and outcomes across massive datasets. Dr. Fuchs founded Paige AI, a leader in AI-based digital pathology, who received the first breakthrough designation for any AI in oncology and the first FDA approval for an AI in pathology. He previously held influential academic roles, including Dean and endowed Barbara T. Murphy professor for AI & Human Health and Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. As inaugural chair, he founded the first department for AI at a medical school in the US and previously was Director of Computational Pathology at Memorial Sloan Kettering Cancer Center. Trained in machine learning at ETH Zurich, with earlier research at the California Institute of Technology and NASA’s Jet Propulsion Laboratory, he now serves as Eli Lilly’s first Chief Artificial Intelligence Officer, guiding AI across drug discovery, clinical development, manufacturing, finance and commercialization

Thomas Fuchs

Biography
Dr.sc. is a pioneer in AI for human health and coined the term Computational Pathology. His deep-learning systems for whole-slide images helped establish clinical-grade AI in oncology and built petabyte-scale AI infrastructure, enabling faster, more accurate diagnosis and accelerating precision treatment decisions across the globe. His research has advanced the field by linking tissue morphology to molecular drivers and outcomes across massive datasets. Dr. Fuchs founded Paige AI, a leader in AI-based digital pathology, who received the first breakthrough designation for any AI in oncology and the first FDA approval for an AI in pathology. He previously held influential academic roles, including Dean and endowed Barbara T. Murphy professor for AI & Human Health and Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. As inaugural chair, he founded the first department for AI at a medical school in the US and previously was Director of Computational Pathology at Memorial Sloan Kettering Cancer Center. Trained in machine learning at ETH Zurich, with earlier research at the California Institute of Technology and NASA’s Jet Propulsion Laboratory, he now serves as Eli Lilly’s first Chief Artificial Intelligence Officer, guiding AI across drug discovery, clinical development, manufacturing, finance and commercialization

Shashi Shankar

Biography
Shashi Shankar is the co-founder and CEO of Novellia, Inc., an award-winning, AI-enabled data partner trusted by leading biopharma companies to uncover hidden insights in real-world patient data. With a background in healthcare and a passion for leveraging AI and data analytics, Shashi leads Novellias strategy and business development to transform health data integration for improved patient outcomes. Prior to founding Novellia, Shashi spent nearly a decade at Genentech and Roche, where his personal experience with fragmented health data deeply motivated him to pioneer solutions that give both patients and researchers a more complete, accessible, and actionable view of healthcare data.